Compile Data Set for Download or QSAR
maximum 50k data
Found 63 Enz. Inhib. hit(s) with all data for entry = 10870
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575834(US11466003, Compound 53)
Affinity DataIC50:  6.90nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575821(US11466003, Compound 40)
Affinity DataIC50:  12nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575831(US11466003, Compound 50)
Affinity DataIC50:  13nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575836(US11466003, Compound 55)
Affinity DataIC50:  13nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575784(US11466003, Compound 2 | US11466003, Compound 43)
Affinity DataIC50:  15nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575826(US11466003, Compound 45)
Affinity DataIC50:  15nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575791(US11466003, Compound 46 | US11466003, Compound 9)
Affinity DataIC50:  16nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575791(US11466003, Compound 46 | US11466003, Compound 9)
Affinity DataIC50:  16nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575784(US11466003, Compound 2 | US11466003, Compound 43)
Affinity DataIC50:  16.5nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575819(US11466003, Compound 38)
Affinity DataIC50:  18nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575785(US11466003, Compound 3 | US11466003, Compound 56)
Affinity DataIC50:  19nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575785(US11466003, Compound 3 | US11466003, Compound 56)
Affinity DataIC50:  27nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575792(US11466003, Compound 10)
Affinity DataIC50:  35nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575811(US11466003, Compound 29)
Affinity DataIC50:  38nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575808(US11466003, Compound 26)
Affinity DataIC50:  38nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575840(US11466003, Compound 59)
Affinity DataIC50:  39nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575790(US11466003, Compound 8)
Affinity DataIC50:  45nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575794(US11466003, Compound 12)
Affinity DataIC50:  45nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575806(US11466003, Compound 24)
Affinity DataIC50:  45nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575839(US11466003, Compound 58)
Affinity DataIC50:  46nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575832(US11466003, Compound 51)
Affinity DataIC50:  48nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575796(US11466003, Compound 14)
Affinity DataIC50:  53nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575838(US11466003, Compound 57)
Affinity DataIC50:  56nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575818(US11466003, Compound 37)
Affinity DataIC50:  63nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575841(US11466003, Compound 60)
Affinity DataIC50:  64nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575803(US11466003, Compound 21)
Affinity DataIC50:  72nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575807(US11466003, Compound 25)
Affinity DataIC50:  73nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575843(US11466003, Compound 63)
Affinity DataIC50:  74nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575788(US11466003, Compound 6)
Affinity DataIC50:  82nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575789(US11466003, Compound 7)
Affinity DataIC50:  85nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575835(US11466003, Compound 54)
Affinity DataIC50:  98nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575830(US11466003, Compound 49)
Affinity DataIC50:  102nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM476220(US10865384, Compound SB431542 | US11447490, Compou...)
Affinity DataIC50:  108nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575805(US11466003, Compound 23)
Affinity DataIC50:  110nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575842(US11466003, Compound 61)
Affinity DataIC50:  114nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575828(US11466003, Compound 47)
Affinity DataIC50:  126nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575813(US11466003, Compound 31)
Affinity DataIC50:  126nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575823(US11466003, Compound 42)
Affinity DataIC50:  144nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575793(US11466003, Compound 11)
Affinity DataIC50:  145nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575783(US11466003, Compound 1)
Affinity DataIC50:  192nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575809(US11466003, Compound 27)
Affinity DataIC50:  193nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575820(US11466003, Compound 39)
Affinity DataIC50:  196nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575815(US11466003, Compound 33)
Affinity DataIC50:  221nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575829(US11466003, Compound 48)
Affinity DataIC50:  237nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575787(US11466003, Compound 5)
Affinity DataIC50:  243nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575825(US11466003, Compound 44)
Affinity DataIC50:  322nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575795(US11466003, Compound 13)
Affinity DataIC50:  337nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575814(US11466003, Compound 32)
Affinity DataIC50:  339nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575797(US11466003, Compound 15)
Affinity DataIC50:  360nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Shanghai Yingli Pharmaceutical

US Patent
LigandPNGBDBM575833(US11466003, Compound 52)
Affinity DataIC50:  415nMAssay Description:1. Preparation of kinase buffer: 40 mM Tris (pH 7.5), 20 mM MgCl2, 0.10% BSA, 1 mM DTT.2. Preparation of the compound: the final concentration of the...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 63 total ) | Next | Last >>
Jump to: